Last week, Merck (NYSE:MRK) released figures about its U.S. pricing practices, joining a growing list of companies that are revealing their pricing strategies amid criticism of the industry’s price hikes.
The company didn’t release price increases of specific products, citing competition concerns. Merck said it would update the list annually at the beginning of each calendar year.
Get the full story at our sister site, Drug Delivery Business News.
The post Merck becomes latest to offer insight into drug pricing practices appeared first on MassDevice.